Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 343, Issue 3, 2012, Pages 556-567

  Hambruch, Eva ^a   Miyazaki Anzai, Shinobu ^b   Hahn, Ulrike ^c   Matysik, Silke ^d   Boettcher, Alfred ^d   Perović Ottstadt, Sanja ^a   Schlüter, Thomas ^a   Kinzel, Olaf ^a   Krol, Helen Desiree ^a   Deuschle, Ulrich ^a   Burnet, Michael ^c   Levi, Moshe ^b   Schmitz, Gerd ^d   Miyazaki, Makoto ^b   Kremoser, Claus ^a  

^a PHENEX PHARMACEUTICALS AG   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Synovo GmbH   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; 4 [2 [2 CHLORO 4[[5 CYCLOPROPYL 3 (2,6 DICHLOROPHENYL) 4 ISOXAZOLYL]METHOXY]PHENYL]CYCLOPROPYL]BENZOIC ACID; 4 [[[6 [[5 CYCLOPROPYL 3 (2,6 DICHLOROPHENYL) 4 ISOXAZOLYL] METHOXY] 2 (TRIFLUOROMETHYL) 3 PYRIDINYL]METHYLAMINO]METHYL]BENZOIC ACID; 6 ETHYL CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HORMONE RECEPTOR STIMULATING AGENT; HYPOCHOLESTEROLEMIC AGENT; LIPID; PX 20350; PX 20606; TRIACYLGLYCEROL; TUROFEXORATE ISOPROPYL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG SYNTHESIS; FAST PROTEIN LIQUID CHROMATOGRAPHY; FEMALE; FLUORESCENCE RESONANCE ENERGY TRANSFER; GLUCOSE BLOOD LEVEL; HAPLORHINI; HUMAN; IN VITRO STUDY; LIPID LIVER LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FECES; FEMALE; HUMANS; LIPOPROTEINS, HDL; LIVER; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, LDL; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84869205703     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.196519     Document Type: Article

References (63)

1. Abel U, Schlüter T, Schulz A, Hambruch E, Steeneck C, Hornberger M, Hoffmann T, Perović-Ottstadt S, Kinzel O, Burnet M, et al. (2010) Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg Med Chem Lett 20:4911-4917.
2. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, and Tall AR (1991) Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J Biol Chem 266:10796-10801. (Pubitemid 21906874)
3. Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, and Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem 276:28857-28865.
4. Arai T, Wang N, Bezouevski M, Welch C, and Tall AR (1999) Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene. J Biol Chem 274:2366-2371.
5. Badellino KO, Wolfe ML, Reilly MP, and Rader DJ (2006) Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 3:e22.
6. Bishop-Bailey D, Walsh DT, and Warner TD (2004) Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A 101:3668-3673. (Pubitemid 38338252)
7. Calkin AC and Tontonoz P (2012) Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 13:213-224.
8. Camont L, Chapman MJ, and Kontush A (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 17:594-603.
9. Cariou B, van Harmelen K, Duran-Sandoval D, van Dijk TH, Grefhorst A, Abdelkarim M, Caron S, Torpier G, Fruchart JC, Gonzalez FJ, et al. (2006) The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 281:11039-11049. (Pubitemid 43855527)
10. Chao F, Gong W, Zheng Y, Li Y, Huang G, Gao M, Li J, Kuruba R, Gao X, Li S, et al. (2010) Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis 213:443-448.
11. Chapman MJ, Goldstein S, Lagrange D, and Laplaud PM (1981) A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 22:339-358. (Pubitemid 11125137)
12. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, et al. (2002) Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 109:961-971. (Pubitemid 34275117)
13. Crawley ML (2010) Farnesoid X receptor modulators: a patent review. Expert Opin Ther Pat 20:1047-1057.
14. Degoma EM and Rader DJ (2011) Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 8:266-277.
15. Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, et al. (2009) A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 296:G543-G552.
16. Fuchs M (2012) Non-alcoholic fatty liver disease: the bile acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012:934396.
17. Gardès C, Blum D, Bleicher K, Chaput E, Ebeling M, Hartman P, Handschin C, Richter H, and Benson GM (2011) Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor. J Lipid Res 52:1188-1199.
18. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6:517-526.
19. Grundy SM, Ahrens EH Jr, and Miettinen TA (1965) Quantitative isolation and gas-liquid chromatographic analysis of total fecal bile acids. J Lipid Res 6:397-410.
20. Guo GL, Santamarina-Fojo S, Akiyama TE, Amar MJ, Paigen BJ, Brewer B Jr, and Gonzalez FJ (2006) Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 1761:1401-1409. (Pubitemid 44822668)
21. Hageman J, Herrema H, Groen AK, and Kuipers F (2010) A role of the bile salt receptor FXR in atherosclerosis. Arterioscler Thromb Vasc Biol 30:1519-1528.
22. Hara A and Radin NS (1978) Lipid extraction of tissues with a low-toxicity solvent. Anal Biochem 90:420-426. (Pubitemid 9062124)
23. -/- mice. J Lipid Res 50:1090-1100.
24. Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Peláez F, et al. (2003) Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 278:51085-51090. (Pubitemid 38020343)
25. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225.
26. Jiang XC, Agellon LB, Walsh A, Breslow JL, and Tall A (1992) Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 90:1290-1295.
27. Lambert G, Amar MJ, Guo G, Brewer HB Jr, Gonzalez FJ, and Sinal CJ (2003) The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 278:2563-2570. (Pubitemid 36801334)
28. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127-135.
29. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, and Mangelsdorf DJ (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621-1624.
30. Kozarsky KF, Donahee MH, Glick JM, Krieger M, and Rader DJ (2000) Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 20:721-727. (Pubitemid 30151687)
31. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, and Krieger M (1997) Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 387:414-417. (Pubitemid 27227207)
32. Kremoser C, Abel U, Steeneck C, and Kinzel O (2011) inventors; Phenex Pharmaceuticals AG, assignee. Novel FXR (NR1H4) binding and activity modulating compounds. World patent WO2011/020615. 2011 Feb 24.
33. Kruit JK, Plösch T, Havinga R, Boverhof R, Groot PH, Groen AK, and Kuipers F (2005) Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 128:147-156. (Pubitemid 40039966)
34. Li G, Thomas AM, Williams JA, Kong B, Liu J, Inaba Y, Xie W, and Guo GL. (2012) Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One 7:e35895.
35. Li YT, Swales KE, Thomas GJ, Warner TD, and Bishop-Bailey D (2007) Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27:2606-2611. (Pubitemid 350158912)
36. Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, Bai L, Abdiche Y, Dilley J, Yu J, et al. (2012) Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther 340:228-236.
37. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, and Mangelsdorf DJ (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507-515.
38. Ma K, Saha PK, Chan L, and Moore DD (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116:1102-1109.
39. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, and Shan B (1999) Identification of a nuclear receptor for bile acids. Science 284:1362-1365. (Pubitemid 29289663)
40. Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG, Lewis MC, et al. (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. J Med Chem 43:2971-2974. (Pubitemid 30626755)
41. Mehlmann JF, Crawley ML, Lundquist JT 4th, Unwalla RJ, Harnish DC, Evans MJ, Kim CY, Wrobel JE, and Mahaney PE (2009) Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR). Bioorg Med Chem Lett 19:5289-5292.
42. Mencarelli A, Renga B, Distrutti E, and Fiorucci S (2009) Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 296:H272-H281.
43. Miettinen TA, Ahrens EH Jr, and Grundy SM (1965) Quantitative isolation and gas-liquid chromatographic analysis of total dietary and fecal neutral steroids. J Lipid Res 6:411-424.
44. -/- mice with chronic kidney disease. Circ Res 106:1807-1817.
45. Nijstad N, Wiersma H, Gautier T, van der Giet M, Maugeais C, and Tietge UJ (2009) Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J Biol Chem 284:6093-6100.
46. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, et al. (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365-1368. (Pubitemid 29289664)
47. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, and Willson TM (2002) 6α-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45:3569-3572. (Pubitemid 34856095)
48. Porez G, Prawitt J, Gross B, and Staels B (2012) Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease: Thematic Review Series: New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases. J Lipid Res 53:1723-1737.
49. Rodríguez-Sureda V and Peinado-Onsurbe J (2005) A procedure for measuring triacylglyceride and cholesterol content using a small amount of tissue. Anal Biochem 343:277-282. (Pubitemid 41074041)
50. Rye KA and Barter PJ (2012) Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim Biophys Acta 1821:473-480.
51. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, and Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744.
52. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, and Burris TP (2005) Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146:984-991. (Pubitemid 40289284)
53. Ueda Y, Royer L, Gong E, Zhang J, Cooper PN, Francone O, and Rubin EM (1999) Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 274:7165-7171.
54. Wang DQ and Carey MC (2003) Measurement of intestinal cholesterol absorption by plasma and fecal dual-isotope ratio, mass balance, and lymph fistula methods in the mouse: an analysis of direct versus indirect methodologies. J Lipid Res 44:1042-1059. (Pubitemid 37279664)
55. Webb NR, Cai L, Ziemba KS, Yu J, Kindy MS, van der Westhuyzen DR, and de Beer FC (2002) The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res 43:1890-1898. (Pubitemid 35315807)
56. Webb NR, de Beer MC, Asztalos BF, Whitaker N, van der Westhuyzen DR, and de Beer FC (2004) Remodeling of HDL remnants generated by scavenger receptor class B type I. J Lipid Res 45:1666-1673. (Pubitemid 39296206)
57. Willson TM, Jones SA, Moore JT, and Kliewer SA (2001) Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism. Med Res Rev 21:513-522. (Pubitemid 32959240)
58. Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, Hobbs HH, and Cohen JC (2005) Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 280: 8742-8747. (Pubitemid 40409561)
59. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, and Rader DJ (2005) Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest 115:2870-2874. (Pubitemid 41434414)
60. Zhang Y and Edwards PA (2008) FXR signaling in metabolic disease. FEBS Lett 582:10-18. (Pubitemid 350297240)
61. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, and Edwards PA (2006a) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103:1006-1011. (Pubitemid 43212212)
62. Zhang Y, Wang X, Vales C, Lee FY, Lee H, Lusis AJ, and Edwards PA (2006b) FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol 26:2316-2321. (Pubitemid 44465728)
63. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, and Edwards PA (2010) Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 285:3035-3043.